Technology evaluation: CpG-7909, Coley.

Abstract

Coley Pharmaceutical (formerly CpG ImmunoPharmaceuticals) is developing CpG-7909 (ProMune) for use in the potential treatment of cancer and as a vaccine adjuvant. By April 2000, CpG-7909 had entered phase I/II trials for cancer and in March 2002, Coley initiated a phase I trial in non-Hodgkin's lymphoma in combination with rituximab (Rituxan). By October 2002, CpG-7909 was in phase II trials as a vaccine adjuvant. Cpg-7909 is currently also undergoing phase II trials for melanoma.

• Authors: Stéphane Paul
• Journal: Current opinion in molecular therapeutics (Curr Opin Mol Ther) Vol. 5 Issue 5 Pg. 553-9 (Oct 2003) ISSN: 1464-8431 [Print] England
• PMID: 14601526 (Publication Type: Clinical Trial, Controlled Clinical Trial, Evaluation Study, Journal Article)

Chemical References

• Adjuvants, Immunologic
• Antineoplastic Agents
• DNA-Binding Proteins
• Oligodeoxyribonucleotides
• Oligodeoxyribonucleotides, Antisense
• ProMune
• Receptors, Cell Surface
• TLR9 protein, human
• Toll-Like Receptor 9

Topics

• Adjuvants, Immunologic (pharmacokinetics, therapeutic use)
• Animals
• Antineoplastic Agents (pharmacokinetics, therapeutic use)
• Clinical Trials, Phase I as Topic
• Clinical Trials, Phase II as Topic
• CpG Islands
• DNA-Binding Proteins (immunology, metabolism)
• Hepatitis B (drug therapy)
• Humans
• Neoplasms (drug therapy)
• Oligodeoxyribonucleotides (pharmacokinetics, therapeutic use)
• Oligodeoxyribonucleotides, Antisense (metabolism)
• Receptors, Cell Surface (immunology, metabolism)
• Toll-Like Receptor 9